F M Investments LLC Reduces Position in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

F M Investments LLC decreased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 68.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 38,626 shares of the medical instruments supplier's stock after selling 84,919 shares during the quarter. F M Investments LLC owned about 0.17% of LeMaitre Vascular worth $3,559,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new position in LeMaitre Vascular during the fourth quarter worth $14,900,000. Martingale Asset Management L P boosted its stake in shares of LeMaitre Vascular by 1.5% during the 4th quarter. Martingale Asset Management L P now owns 21,994 shares of the medical instruments supplier's stock worth $2,027,000 after purchasing an additional 321 shares during the period. Renaissance Technologies LLC grew its holdings in LeMaitre Vascular by 0.8% during the 4th quarter. Renaissance Technologies LLC now owns 163,800 shares of the medical instruments supplier's stock valued at $15,093,000 after purchasing an additional 1,300 shares during the last quarter. Legal & General Group Plc raised its position in LeMaitre Vascular by 2.4% in the 4th quarter. Legal & General Group Plc now owns 57,753 shares of the medical instruments supplier's stock worth $5,321,000 after purchasing an additional 1,339 shares during the period. Finally, Invesco Ltd. lifted its stake in LeMaitre Vascular by 50.5% in the fourth quarter. Invesco Ltd. now owns 174,998 shares of the medical instruments supplier's stock worth $16,124,000 after purchasing an additional 58,720 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on LMAT. Wells Fargo & Company started coverage on LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 price target on the stock. Oppenheimer lowered shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Barrington Research downgraded shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Finally, Lake Street Capital boosted their price objective on shares of LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Five analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $95.25.

LeMaitre Vascular Price Performance

NASDAQ LMAT traded up $0.85 during midday trading on Tuesday, hitting $84.63. 145,116 shares of the company traded hands, compared to its average volume of 159,288. LeMaitre Vascular, Inc. has a 52 week low of $62.39 and a 52 week high of $109.58. The company's 50-day simple moving average is $88.88 and its 200-day simple moving average is $93.68. The company has a market cap of $1.91 billion, a PE ratio of 46.25, a price-to-earnings-growth ratio of 2.22 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 EPS for the quarter, hitting analysts' consensus estimates of $0.49. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.15%. The business had revenue of $55.81 million during the quarter, compared to the consensus estimate of $55.99 million. On average, research analysts predict that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current year.

LeMaitre Vascular Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 27th. Stockholders of record on Thursday, March 13th were given a $0.20 dividend. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.16. The ex-dividend date was Thursday, March 13th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.95%. LeMaitre Vascular's dividend payout ratio (DPR) is presently 41.24%.

Insider Buying and Selling

In other LeMaitre Vascular news, insider Trent G. Kamke sold 2,009 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $82.12, for a total value of $164,979.08. Following the completion of the sale, the insider now owns 5,564 shares of the company's stock, valued at approximately $456,915.68. This trade represents a 26.53 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.79% of the stock is owned by company insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.